Genetron - GTH Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genetron in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Genetron stock.
View analyst ratings for Genetron or view top-rated stocks.

1 brokers have issued 12-month target prices for Genetron's stock. Their GTH stock forecasts range from $10.00 to $10.00. On average, they expect Genetron's share price to reach $10.00 in the next year. This suggests a possible upside of 953.5% from the stock's current price.
View analysts' price targets for Genetron or view top-rated stocks among Wall Street analysts.

Genetron's stock was trading at $6.10 at the start of the year. Since then, GTH shares have decreased by 84.4% and is now trading at $0.9492.
View the best growth stocks for 2022 here.

Genetron saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 1,060,000 shares, a decrease of 29.8% from the June 30th total of 1,510,000 shares. Based on an average trading volume of 244,100 shares, the short-interest ratio is currently 4.3 days. Currently, 1.3% of the shares of the company are short sold.
View Genetron's Short Interest.

Genetron is scheduled to release its next quarterly earnings announcement on Tuesday, August 23rd 2022.
View our earnings forecast for Genetron.

Genetron Holdings Limited (NASDAQ:GTH) released its quarterly earnings results on Thursday, June, 2nd. The company reported ($0.30) EPS for the quarter. The business had revenue of $17.40 million for the quarter. Genetron had a negative net margin of 101.62% and a negative trailing twelve-month return on equity of 43.57%.

Genetron issued an update on its FY 2022 earnings guidance on Thursday, June, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $92.28 million-$100.64 million, compared to the consensus revenue estimate of $92.50 million.

(GTH) raised $162 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 13,000,000 shares at a price of $11.50-$13.50 per share. Credit Suisse and CICC acted as the underwriters for the IPO and BTIG and Canaccord Genuity were co-managers.

Genetron trades on the NASDAQ under the ticker symbol "GTH."

Genetron's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Legacy Wealth Asset Management LLC (0.02%).

Shares of GTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GTH stock can currently be purchased for approximately $0.95.

Genetron (NASDAQ:GTH) has a market capitalization of $86.00 million and generates $83.47 million in revenue each year. The company earns $-77,870,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

Genetron employs 1,154 workers across the globe.

Genetron's mailing address is 1-2/F BUILDING 11 ZONE 1 CHANGPING DISTRICT, BEIJING F4, 102206. The official website for Genetron is www.genetronhealth.com. The company can be reached via phone at 86-10-5090-7500 or via email at ir@genetronhealth.com.